Premium
Dynamic genome and transcriptional network‐based biomarkers and drugs: precision in breast cancer therapy
Author(s) -
Kyrochristos Ioannis D.,
Ziogas Demosthenes E.,
Roukos Dimitrios H.
Publication year - 2019
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21549
Subject(s) - computational biology , breast cancer , genome , biology , cancer genome sequencing , genomics , dna sequencing , gene , bioinformatics , cancer , genetics
Abstract Despite remarkable progress in medium‐term overall survival benefit in the adjuvant, neoadjuvant and metastatic settings, with multiple recent targeted drug approvals, acquired resistance, late relapse, and cancer‐related death rates remain challenging. Integrated technological systems have been developed to overcome these unmet needs. The characterization of structural and functional noncoding genome elements through next‐generation sequencing (NGS) systems, Hi‐C and CRISPR/Cas9, as well as computational models, allows for whole genome and transcriptome analysis. Rapid progress in large‐scale single‐biopsy genome analysis has identified several novel breast cancer driver genes and oncotargets. The exploration of spatiotemporal tumor evolution has returned exciting while inconclusive data on dynamic intratumor heterogeneity (ITH) through multiregional NGS and single‐cell DNA/RNA sequencing and circulating genomic subclones (cGSs) by serial circulating cell‐free DNA NGS to predict and overcome intrinsic and acquired therapeutic resistance. This review discusses reliable breast cancer genome analysis data and focuses on two major crucial perspectives. The validation of ITH, cGSs, and intrapatient genetic/genomic heterogeneity as predictive biomarkers, as well as the valid discovery of novel oncotargets within patient‐centric genomic trials, encouraging early drug development, could optimize primary and secondary therapeutic decision‐making. A longer‐term goal is to identify the individualized landscape of both coding and noncoding key mutations. This progress will enable the understanding of molecular mechanisms perturbating regulatory networks, shaping the pharmaceutical controllability of deregulated transcriptional biocircuits.